295 related articles for article (PubMed ID: 20683646)
1. Cholesterol as a potential target for castration-resistant prostate cancer.
Twiddy AL; Leon CG; Wasan KM
Pharm Res; 2011 Mar; 28(3):423-37. PubMed ID: 20683646
[TBL] [Abstract][Full Text] [Related]
2. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.
Leon CG; Locke JA; Adomat HH; Etinger SL; Twiddy AL; Neumann RD; Nelson CC; Guns ES; Wasan KM
Prostate; 2010 Mar; 70(4):390-400. PubMed ID: 19866465
[TBL] [Abstract][Full Text] [Related]
3. Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells.
Yenki P; Bhasin S; Liu L; Nabavi N; Cheng CW; Tam KJ; Peacock JW; Adomat HH; Tombe T; Fazli L; Ivanova L; Dusek C; Khosravi S; Guns EST; Wang Y; Buttyan R; Gleave ME; Ong CJ
Endocr Relat Cancer; 2023 Dec; 30(12):. PubMed ID: 37800655
[TBL] [Abstract][Full Text] [Related]
4. Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance.
Locke JA; Guns ES; Lehman ML; Ettinger S; Zoubeidi A; Lubik A; Margiotti K; Fazli L; Adomat H; Wasan KM; Gleave ME; Nelson CC
Prostate; 2010 Feb; 70(3):239-51. PubMed ID: 19790237
[TBL] [Abstract][Full Text] [Related]
5. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
Locke JA; Guns ES; Lubik AA; Adomat HH; Hendy SC; Wood CA; Ettinger SL; Gleave ME; Nelson CC
Cancer Res; 2008 Aug; 68(15):6407-15. PubMed ID: 18676866
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of Scavenger Receptor B1 Is Required for Steroidogenic and Nonsteroidogenic Cholesterol Metabolism in Prostate Cancer.
Gordon JA; Noble JW; Midha A; Derakhshan F; Wang G; Adomat HH; Tomlinson Guns ES; Lin YY; Ren S; Collins CC; Nelson PS; Morrissey C; Wasan KM; Cox ME
Cancer Res; 2019 Jul; 79(13):3320-3331. PubMed ID: 31064850
[TBL] [Abstract][Full Text] [Related]
7. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors.
Mostaghel EA; Solomon KR; Pelton K; Freeman MR; Montgomery RB
PLoS One; 2012; 7(1):e30062. PubMed ID: 22279565
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
[TBL] [Abstract][Full Text] [Related]
9. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
Montgomery RB; Mostaghel EA; Vessella R; Hess DL; Kalhorn TF; Higano CS; True LD; Nelson PS
Cancer Res; 2008 Jun; 68(11):4447-54. PubMed ID: 18519708
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.
Shiota M; Yokomizo A; Naito S
Free Radic Biol Med; 2011 Oct; 51(7):1320-8. PubMed ID: 21820046
[TBL] [Abstract][Full Text] [Related]
11. Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer.
El-Kenawi A; Dominguez-Viqueira W; Liu M; Awasthi S; Abraham-Miranda J; Keske A; Steiner KK; Noel L; Serna AN; Dhillon J; Gillies RJ; Yu X; Koomen JM; Yamoah K; Gatenby RA; Ruffell B
Cancer Res; 2021 Nov; 81(21):5477-5490. PubMed ID: 34301759
[TBL] [Abstract][Full Text] [Related]
12. Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis.
Xu Z; Ma T; Zhou J; Gao W; Li Y; Yu S; Wang Y; Chan FL
Theranostics; 2020; 10(9):4201-4216. PubMed ID: 32226548
[TBL] [Abstract][Full Text] [Related]
13. Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer.
Yamaoka M; Hara T; Kusaka M
Clin Cancer Res; 2010 Sep; 16(17):4319-24. PubMed ID: 20647476
[TBL] [Abstract][Full Text] [Related]
14. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
15. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
16. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N
Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
[TBL] [Abstract][Full Text] [Related]
17. Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts.
Locke JA; Nelson CC; Adomat HH; Hendy SC; Gleave ME; Guns ES
J Steroid Biochem Mol Biol; 2009 Jul; 115(3-5):126-36. PubMed ID: 19442514
[TBL] [Abstract][Full Text] [Related]
18. The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.
Fiandalo MV; Wu W; Mohler JL
Curr Drug Targets; 2013 Apr; 14(4):420-40. PubMed ID: 23565755
[TBL] [Abstract][Full Text] [Related]
19. Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment.
Lubik AA; Nouri M; Truong S; Ghaffari M; Adomat HH; Corey E; Cox ME; Li N; Guns ES; Yenki P; Pham S; Buttyan R
Int J Cancer; 2017 Jan; 140(2):358-369. PubMed ID: 27672740
[TBL] [Abstract][Full Text] [Related]
20. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
Tsao CK; Galsky MD; Small AC; Yee T; Oh WK
BJU Int; 2012 Dec; 110(11):1580-8. PubMed ID: 22985411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
